Loading
A phase 1/2 trial of Oral MRT-2359 in non-small-cell lung cancer, small-cell lung cancer, neuroendocrine tumours, HR-positive / HER2-negative breast cancer and prostate cancer, run by Monte Rosa Therapeutics, Inc, active and no longer recruiting.
Study of Oral MRT-2359 in Selected Cancer Patients is a phase 1/2 interventional study registered as NCT05546268 by Monte Rosa Therapeutics, Inc, with 174 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2026-05. Interventions recorded: Oral MRT-2359.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HR-positive / HER2-negative breast cancer, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/